Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 November 2006Website:
http://www.catalystpharma.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
CPRX Latest News
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ET
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
CPRX, HCI, DXC, CRAI and CRUS have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2024.
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE® (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome ("LEMS") in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.
What type of business is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
What sector is Catalyst Pharmaceuticals in?
Catalyst Pharmaceuticals is in the Healthcare sector
What industry is Catalyst Pharmaceuticals in?
Catalyst Pharmaceuticals is in the Biotechnology industry
What country is Catalyst Pharmaceuticals from?
Catalyst Pharmaceuticals is headquartered in United States
When did Catalyst Pharmaceuticals go public?
Catalyst Pharmaceuticals initial public offering (IPO) was on 08 November 2006
What is Catalyst Pharmaceuticals website?
https://www.catalystpharma.com
Is Catalyst Pharmaceuticals in the S&P 500?
No, Catalyst Pharmaceuticals is not included in the S&P 500 index
Is Catalyst Pharmaceuticals in the NASDAQ 100?
No, Catalyst Pharmaceuticals is not included in the NASDAQ 100 index
Is Catalyst Pharmaceuticals in the Dow Jones?
No, Catalyst Pharmaceuticals is not included in the Dow Jones index
When was Catalyst Pharmaceuticals the previous earnings report?
No data
When does Catalyst Pharmaceuticals earnings report?
The next expected earnings date for Catalyst Pharmaceuticals is 07 November 2024